Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal hemoglobinuria (PNH) therapies as well as novel agents and combinations targeting the ...
Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida, is rapidly approaching. Clinicians from around the world are preparing for the newest data that may ...
From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma. It’s that time of the year again; the 2025 ...
Suchitra Sundaram, MD, shares that ASH 2025 presented major advances in chronic lymphocytic leukemia (CLL) across both time‑limited and continuous treatment strategies, and emphasized the growing role ...
Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results